1. Home
  2. Companies
  3. CU6
  4. Material Events

Clarity Pharmaceuticals (ASX:CU6) — Material Events

ASX:CU6 · 22 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Major 6 articles Significant 15 articles Notable 1 article Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Major Score 90+
6
Clarity Pharmaceuticals Secures $203M to Advance Copper-Based Cancer TherapiesHigh
Clarity Pharmaceuticals raises $203M, advances copper-based cancer diagnostics and therapies with multiple FDA Fast Track trials
25 Nov 2025 ·Annual General Meeting Presentation ·90
Clarity’s Cu-64 SAR-bisPSMA Doubles Prostate Cancer Lesion Detection in Key TrialHigh
Clarity’s Cu-64 SAR-bisPSMA doubles prostate cancer lesion detection vs Ga-68 PSMA-11 in pivotal trial
16 Feb 2026 ·Clinical Trial Results Announcement ·90
Clarity Pharmaceuticals Secures $203M to Accelerate Cancer Drug TrialsHigh
Clarity Pharmaceuticals raises $203M in premium institutional placement to fund pivotal cancer drug trials
28 July 2025 ·Capital Raising ·90
Significant Score 75–89
15
Clarity Pharmaceuticals Secures Major Copper-64 Supply Deal with TheragenicsMedium
Clarity Pharmaceuticals inks major copper-64 supply deal with Theragenics ahead of Cu-SAR-bisPSMA commercial launch
25 Mar 2026 ·Manufacturing Supply Agreement Announcement ·85
Clarity Pharmaceuticals Advances Prostate Cancer Trials with $226M Cash BufferMedium
Clarity Pharmaceuticals advances clinical trials and supply chain with strong cash position
30 Jan 2026 ·Quarterly Activity Report and Appendix 4C ·85
Clarity’s Cu-SAR-bisPSMA Shows Superior Prostate Cancer Detection Ahead of EAU 2026Medium
Clarity's Cu-SAR-bisPSMA Trial Accepted for Oral Presentation at EAU 2026, Shows Superior Prostate Cancer Detection
24 Dec 2025 ·Clinical Trial Update ·85
Clarity Expands US Manufacturing Capacity for Prostate Cancer Imaging AgentMedium
Clarity signs manufacturing deal with Nucleus RadioPharma for prostate cancer imaging agent
14 Apr 2026 ·Commercial Manufacturing Agreement ·85
Clarity Pharmaceuticals Advances Clinical Pipeline Amid $64.3M Loss and $203.6M Capital RaiseHigh
Clarity Pharmaceuticals reports $64.3M loss, advances clinical trials, raises $203.6M for growth
28 Aug 2025 ·Appendix 4E Preliminary Final Report ·85
Clarity Pharmaceuticals Showcases Superior Prostate Cancer Imaging and Therapy Data at EANM 2026Medium
Clarity Pharmaceuticals to present promising prostate cancer imaging and therapy data at EANM 2026
29 June 2026 ·Clinical Trial Data Presentation ·85
Clarity Pharmaceuticals Advances Cu-64 SARTATE to Pivotal Phase III Trial After FDA NodMedium
Clarity Pharmaceuticals to start pivotal Phase III trial of Cu-64 SARTATE for neuroendocrine tumours following positive FDA guidance
22 Dec 2025 ·Clinical Trial Announcement ·85
Clarity Pharmaceuticals Advances SECuRE Trial with Promising Prostate Cancer ResultsMedium
Clarity Pharmaceuticals' SECuRE Phase II trial continues with positive interim safety and efficacy results
15 Jan 2026 ·Clinical Trial Update ·85
Clarity’s Cu-SAR-bisPSMA Outperforms Standard Imaging in Prostate Cancer TrialMedium
Clarity's Co-PSMA trial meets primary endpoint, showing superior prostate cancer lesion detection with Cu-SAR-bisPSMA
14 Oct 2025 ·Clinical Trial Results Announcement ·85
Clarity’s Cu-SAR-bisPSMA Outperforms Standard Imaging in Prostate Cancer RecurrenceMedium
Clarity’s Cu-SAR-bisPSMA shows superior prostate cancer detection in Phase II Co-PSMA trial; data accepted in top urology journal
17 Mar 2026 ·Clinical Trial Results Announcement ·85
Clarity Pharmaceuticals Hits Target in Pivotal Prostate Cancer Imaging TrialMedium
Clarity Pharmaceuticals completes enrolment in Phase III AMPLIFY trial for prostate cancer imaging agent
10 Mar 2026 ·Clinical Trial Update ·85
Clarity Pharmaceuticals Hits Fifth Undetectable Prostate Cancer Case in SECuRE TrialMedium
Clarity Pharmaceuticals reports fifth patient with undetectable prostate cancer markers in Phase II SECuRE trial
23 Feb 2026 ·Clinical Trial Update ·85
Clarity Pharmaceuticals Secures Key Copper-67 Supply for Prostate Cancer TrialsMedium
Clarity Pharmaceuticals secures copper-67 supply agreement with Nusano for clinical and commercial use
16 Oct 2025 ·Supply Agreement Announcement ·80
Clarity Pharmaceuticals Posts $55.6M Half-Year Loss, Winds Up European ArmMedium
Clarity Pharmaceuticals reports $55.6M half-year loss and winds up European subsidiary
27 Feb 2026 ·Appendix 4D ·Unexpected ·75
Clarity Pharmaceuticals Completes Key Prostate Cancer Imaging Trial RecruitmentMedium
Clarity Pharmaceuticals completes recruitment for Co-PSMA trial evaluating Cu-SAR-bisPSMA in prostate cancer detection
17 July 2025 ·Clinical Trial Update ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.